NCT06569706 Feasibility and Acceptability of Endoscopic Mastectomy in Patients With Breast Cancer
| NCT ID | NCT06569706 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Montpellier |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-10-18 |
| Primary Completion | 2026-10-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-10-18 with a primary completion date of 2026-10-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Nipple -Sparing Mastectomy (NSM), with immediate breast reconstruction (IBR) can be offered to patients requiring mastectomy when the lesion is more than 2cm from the nipple. Endoscopic mastectomy is a technical alternative for small-volume breasts (cup sizes A, B, C), offering a NSM with IBR, but also concealing the scar on the axillary line. It can be performed with traditional laparoscopic equipment, making this technique much more accessible and less costly than robotic mastectomy. It uses a single-port device that is significantly less costly than robotic equipment. Feasibility and safety studies remain limited to the Asian continent, and it would undoubtedly be beneficial to initiate research in Europe to add this new technical option to our surgical arsenal. This study project aims to explore the feasibility and safety of endoscopic nipple-sparing mastectomy for breast cancer indications in a French center.
Eligibility Criteria
Inclusion Criteria: * Women between 20 and 75 years. * Patient with an indication for curative mastectomy, either unilateral or bilateral, with nipple preservation: * Extensive Carcinoma In Situ (CIS), more than 2 cm from the nipple * Multicentric Infiltrating Carcinoma (IC), more than 2 cm from the nipple * Large volume Infiltrating Carcinoma, more than 2 cm from the nipple * IC or CIS for which the patient refuses conservative treatment, more than 2 cm from the nipple * Breast volumes: cup sizes A, B, or C as defined by underwear size, and glandular ptosis not exceeding grade 2 according to Regnault's classification * Patient wishing to undergo immediate breast reconstruction. * WHO/OMS (World Health Organization/Organisation Mondiale de la Santé) performance status \<3 Exclusion Criteria: * Cutaneous carcinoma * Inflammatory breast * History of oncological breast surgery on the same breast * Patient who has received radiation treatment on the same breast * Breast hypertrophy requiring a nipple-bearing flap * Smoking ≥ 10 cigarettes/day * BMI \> 35 * Protected patient or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP). * Patient participating in another interventional clinical study. * ASA (physical status score of the American Society of Anesthesiologists) \>2. * Pregnant or breastfeeding women according to Article L1121-5 of the CSP. * Vulnerable persons (those receiving psychiatric care, those deprived of liberty, and those admitted to a health or social institution) according to Article L1121-6 of the CSP. * Absence of effective contraception for patients of childbearing age. * Absence of affiliation with a social security scheme. * Absence of collected free, informed, and written consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06569706 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 75 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06569706 currently recruiting?
Yes, NCT06569706 is actively recruiting participants. Contact the research team at g-rathat@chu-montpellier.fr for enrollment information.
Where is the NCT06569706 trial being conducted?
This trial is being conducted at Montpellier, France.
Who is sponsoring the NCT06569706 clinical trial?
NCT06569706 is sponsored by University Hospital, Montpellier. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.